Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS

Objective: We aimed to evaluate alirocumab- and evolocumab-related adverse events (AEs) in real-world compared with all other drugs, overall and by gender and age subgroups; we also aimed to compare their risks of cognitive impairment, musculoskeletal disorders and diabetes with various statins and...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Zhen, Li, Xiaoye, Tong, Wai Kei, He, Qingfeng, Zhu, Xiao, Xiang, Xiaoqiang, Tang, Zhijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729267/
https://www.ncbi.nlm.nih.gov/pubmed/36506552
http://dx.doi.org/10.3389/fphar.2022.894685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729267/
https://www.ncbi.nlm.nih.gov/pubmed/36506552
http://dx.doi.org/10.3389/fphar.2022.894685

Ejemplares similares